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Abstract
The 2 major types of neurodegeneration with brain iron accumulation (NBIA) are the pantothenate kinase type 2 (PANK2)-associated
neurodegeneration (PKAN) and NBIA2 or infantile neuroaxonal dystrophy (INAD) due to mutations in the phospholipase A2, group VI
(PLA2G6) gene. We have recently demonstrated clinical heterogeneity in patients with mutations in the PLA2G6 gene by identifying a
poorly defined subgroup of patients who present late with dystonia and parkinsonism. We report the clinical and genetic features of 7 cases
with PLA2G6 mutations. Brain was available in 5 cases with an age of death ranging from 8 to 36 years and showed widespread
alpha-synuclein-positive Lewy pathology, which was particularly severe in the neocortex, indicating that the Lewy pathology spread
corresponded to Braak stage 6 and was that of the “diffuse neocortical type”. In 3 cases there was hyperphosphorylated tau accumulation
in both cellular processes as threads and neuronal perikarya as pretangles and neurofibrillary tangles. Later onset cases tended to have less
tau involvement but still severe alpha-synuclein pathology. The clinical and neuropathological features clearly represent a link between
PLA2G6 and parkinsonian disorders.
© 2012 Elsevier Inc.
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Open access under CC BY license.1. Introduction
In the early part of the twentieth century the work of
Seitelberger (Hallervorden and Spatz, 1922; Seitelberger,
1971) and others described the clinicopathological features
of the 2 commonest forms of neurodegeneration with iron
deposition, that is neuroaxonal dystrophy (NAD) and
Hallervorden-Spatz disease, now renamed neurodegenera-
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dom. Tel.: 44 2078373611  4391; fax: 44 2072785616.
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0197-4580 © 2012 Elsevier Inc.
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Open access under CC BY license.tion with brain iron accumulation (NBIA) (Gregory et al.,
2009).
The 2 major types of NBIA are recessively inherited
disorders, NBIA type 1 is due to mutations in the pantothe-
nate kinase 2 gene (PANK2) and often called pantothenate
kinase associated neurodegeneration (PKAN) (Hayflick et
al., 2003; Zhou et al., 2001) and NBIA type 2 or infantile
neuroaxonal dystrophy (INAD) (previously Seitelberger’s
disease) is due to mutations in the phospholipase A2, group
VI (PLA2G6) gene (Khateeb et al., 2006; Morgan et al.,
2006; Seitelberger, 1971). According to the age of onset and
progression, NAD can be separated into: (1) infantile or
classical type (INAD), and (2) juvenile/adult onset or atyp-
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815C. Paisán-Ruiz et al. / Neurobiology of Aging 33 (2012) 814–823ical NAD. A further group comprises idiopathic NBIA
where there is brain iron on imaging but no genetic abnor-
mality in the PLA2G6 and PANK2 genes (Gregory et al.,
009; Morgan et al., 2006). Two other genes also cause
BIA, acoeruloplasminaemia due to mutations in the (ce-
uloplasmin) CP gene (Morita et al., 1992) and neuroferri-
inopathy, caused by mutations in the FTL (ferritin light
olypeptide) gene. Patients with mutation of these 2 genes
sually present with an adult onset movement disorder
Curtis et al., 2001). The vast majority of PKAN cases have
maging evidence of high iron accumulation but this is only
resent in half the cases with PLA2G6 mutations. PKAN
ccounts for approximately 50% of the cases with NBIA
Hayflick et al., 2006; Khateeb et al., 2006; Morgan et al.,
006). Recently families with adult onset dystonia-parkin-
onism were found to have mutations in the PLA2G6 gene
ut absent iron deposition on magnetic resonance imaging
MRI) (Paisan-Ruiz et al., 2009; Sina et al., 2009).
The clinical phenotype of NBIA is broad, although there
re some characteristic features (Gregory et al., 2009; Hay-
ick et al., 2003). Most cases present before the age of 5
ears with developmental delay, dystonia, rigidity, dysar-
hria, and ataxia. Onset between 2 and 18 years is charac-
eristic for the juvenile type and onset after 18 years for the
dult type or atypical NAD. The finding of patients with
LA2G6 mutations and L-dopa responsive adult onset
ystonia-parkinsonism adds a later onset subgroup to the
BIA clinical spectrum. MRI has been of great importance
n distinguishing the clinical and genetic forms of NBIA. In
ases with PKAN mutations a region of hyperintensity (ne-
rosis or edema) in the globus pallidus is seen with sur-
ounding hypodensity (region of high iron) on T2-weighted
mages (Hayflick et al., 2006). This “eye of the tiger” sign
s associated with mutations in the PANK2 gene (Arawaka
t al., 1998; Barbosa et al., 1995; Galvin et al., 2000;
uillerman, 2000; Hajek et al., 2005; Hayflick and West-
way, 2006; Hermann et al., 2000) but is not pathogno-
onic (McNeill et al., 2008). In classical INAD, abnormal
ron mainly accumulates in the globus pallidus and some-
imes in the substantia nigra in the more atypical cases
Gregory et al., 2009; Hayflick et al., 2003).
In the past it has been possible to differentiate NAD from
KAN pathologically mainly by the distribution of dystro-
hic neuroaxonal swellings (spheroids). These have been
hown by immunohistochemistry to be immunoreactive for
eurofilament, amyloid precursor protein, ubiquitin, and
lpha-synuclein (Arawaka et al., 1998; Galvin et al., 2000;
regory et al., 2009; Neumann et al., 2000; Newell et al.,
999; Odawara et al., 1992; Saito et al., 2000; Sugiyama et
l., 1993; Tofaris et al., 2007; Tuite et al., 1996; Waka-
ayashi et al., 1999), although larger spheroids may be
egative for neurofilament. However, with identification of
he PLA2G6 gene, it has become clear that there is also
athological heterogeneity in NAD, as cases with clinical
nd pathological features of INAD were found to be nega- cive for PLA2G6 mutations and patients with PLA2G6 mu-
ations have been identified without axonal spheroids (Greg-
ry et al., 2009). The neuropathological examination of only
case with a confirmed PLA2G6 mutation has been re-
orted in a patient with atypical neuroaxonal dystrophy and
n age of onset of 3 years. This case had typical axonal
pheroids, iron deposition, Lewy bodies, and Lewy neurites
n the substantia nigra and cortex as well as tau immuno-
eactive tangles (Gregory et al., 2009).
To expand the neuropathological spectrum of neuroax-
nal dystrophy caused by PLA2G6 mutations and investi-
ate the overlap with other parkinsonian disorders, we iden-
ified 7 genetically-proven cases with infantile through to
dult onset disease and report the clinical and neuropatho-
ogical features.
. Methods
This project was approved by the Joint Local Research
thics Committee of the National Hospital for Neurology
nd Neurosurgery. Brains are stored in the Queen Square
rain Bank, London (QSBB) and the Brain and Tissue
anks for Developmental Disorders, Baltimore (BTBDD)
y obtaining appropriate consents.
.1. Patients
The clinical features of the patients examined are de-
cribed in the results section and Table 1. Cases 1 and 2
ere from the QSBB. Cases 3–6 were from the National
nstitute of Child Health and Human Development
NICHD), Brain and Tissue Bank for Developmental Dis-
rder. Tissue from these disorders is rare as brain donation
s not frequently made by families; we contacted as many
rain banks as possible to obtain tissue from cases with a
oung onset complex dystonia or parkinsonian disorder. In
ases 1, 2, and 4 detailed clinical notes were available, clinical
etails in cases 3 and 5 were minimal. Cases 1, 3, 4, and 5
nderwent detailed neuropathological examination. Tissue
rom a cortical biopsy was available in case 2. The neuropatho-
ogical findings of case 2 (Tofaris et al., 2007) and case 5
Galvin et al., 2000) had been reported earlier. Two further
ases (case 6 and 7) only had a sural nerve biopsy carried out.
.2. Genetics
DNA was extracted from brain tissue or blood using a
tandard phenol chloroform method. All exons of the
ANK2 gene were sequenced as was exon 4 of the ferritin
ight chain gene (the only exon shown to have mutations)
Curtis et al., 2001) as both genes have an NBIA phenotype
nd were found to be negative.
All 16 coding exons of the PLA2G6 gene (reference
equence NM_003560) were sequenced, as with the other
enes given above, using standard Sanger PCR sequencing
Roche Faststart Mastermix, Roche, Indianapolis), purifi-
ation (Millipore, Billerica, MA), Bigdye (ABI/Perkin El-
PP
F
O
2
K
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(ABgene, Epsom, UK) and running on an ABI3730XL
sequencer. Primers were designed to amplify each gene
exon and flanking 50 bp intronic sequences (Table 1). The
controls screened were from the UK Wellcome trust 1958
birth cohort and the Centre d’Etude du Polymorphisme
Humain (CEPH) Human Genome Diversity Panel (HGDP),
these samples are available from the Wellcome trust or
CEPH. Mutations were numbered from the ATG start site of
the PLA2G6 gene.
2.3. Neuropathology
The entire brain was examined in case 1; paraffin blocks
from representative brain areas were available from case 4.
In case 2 frontal cortical biopsy tissue was available and
frozen material was only available from case 3. Seven m
thick tissue sections were stained with hematoxylin and
eosin, Luxol fast blue cresyl violet, Perl’s stain for iron and
Gallyas silver methods. Immunohistochemistry was per-
formed with antibodies to glial fibrillary acidic protein
(Dako, 1:1000, Ely, UK), alpha-synuclein (Novocastra,
1:50, Newcastle, UK), phospho-alpha-synuclein (Abcam,1:
1000, Cambridge, UK), tau (AT8, Autogen Bioclear, 1:500,
Nottingham, UK), AT100, Autogen Bioclear 1:200, Not-
Table 1
PCR and sequencing primers used to amplify PLA2G6, PANK2 and FTL
Forward sequence (5= to 3=)
LA2G6
Exon 2 GTGTCTGTGCAGGAAACCG
Exon 3 TGATTCCAGCAGGGATGTG
Exon 4 AAAGTCCGAGTTTCCGAGT
Exon 5 GTGATCCACCCACCTTGG
Exon 6 CTTCATCCCACGCCACG
Exon 7 TCAGAGCAGAAGTGGCAGT
Exon 8 CTGGGTGAGTTGACAGGTT
Exon 9 AGTGTGGAAAGGAGGGGC
Exon 10 CTAGGGACCTCTGGGGTAG
Exon 11 ACAAGGGCTATGAGGGTGG
Exon 12 GCTCTGCAGGCTGTTCTAC
Exon 13 GTGTGAATTGTGGGGAAAG
Exon 14 CTGAGATCTGGAGTGCATG
Exon 15 CCCCAGAGCCCAGTCTTG
Exon 16 CTGACTCGAAAGAGCCTGG
Exon 17 ACCCTGGTCCTAGCTGGC
ANK2
Exon 1A GCTCTATTCCAGAGACCGA
Exon 1B ACCAGCCTGGACAACATAG
Exon 2 TTTCAGCACTTAGTTCACTT
Exon 3 TTATTAAGAGGACTGTGTG
Exon 4 TTTACTTCATGTGATGCCAG
Exon 5 GCACTGTACTTCTTCCATGA
Exon 6 TTGTTGTAGATGATGCATA
Exon 7 ACTGTTTAATGCAGGACGA
TL
Exon 4 GCCTCATTTCACACCTGTC
ligonucleotide primers used to amplify the exonic regions and flanking
(PANK2) and the ferritin light chain (FTL) genes.
ey: PCR, polymerase chain reaction.tingham, UK), ubiquitin (Dako, 1:200, Ely, UK), p62 (BDTransduction, 1:100, Oxford, UK, neurofilament (RT97
Novocastra, 1:50, Newcastle, UK), SMI31 Sternberger
Monoclonals, 1:5000, Cambridge, UK), anti-mouse or
anti-rabbit secondary antibody (Dako, Ely, UK) was used
as appropriate, followed by incubation with ABC (Vec-
tor, Peterborough, UK). Color was developed by di-
aminobenzidine/H2O2. Sections were counterstained with
Mayer’s hematoxylin.
3. Results
Clinical details are summarized in Table 2. Cases 1 and
2 were from the host brain bank where complete clinical
details were available, cases 3–7 were from another brain
bank where copies of the clinical notes were obtained but
these cases had not been seen by any of the coauthors. Cases
3, 5, 6, and 7 all had the typical clinical features of classical
NAD with psychomotor regression at around 1 year of age
and progressive loss of ambulation before aged 5 years. All
cases had progressive cognitive and developmental deteri-
oration, with ataxia, speech, and swallowing problems. Vi-
sual problems occurred in case 3 (bilateral optic atrophy)
and case 6, bilateral hearing loss, seizures, flaccidity, and
muscle cramps in case 5. Imaging demonstrated cerebellar
Reverse sequence (5= to 3=)
GCCAATAAGACCTCCAATCC
AACTATGGAGGGGAACCGAG
AGGCCTGAGAGTGACACCTG
TGGTGGATACTGCTTGCCTC
GAACCTGCTTCCTGAGGG
GGGAGGAGGGCTCCAGTC
ACTTCCCTCCTCCTCGGTC
GATCCTGTTGCTTTGGTGG
GTGAGGGGCAGGAAAGC
GCAAAGCCCTGAAGACAAAC
CTCAGCAGGACAGGGAGC
GATGGCAAGTGCACGACTC
GTCCCTAGCATGGTTTGCTG
AGGATGAGGGGAAGCCATC
GGGAACAGAGCAGACCCTTG
GGCAGGGGTACGGTTGTG
ATTTCCAACTTGAAATCTAACCAG
GACTGGAACAGAATTCAACTGAG
CCAGAACTTCACCAATATAGCAC
CTCATATTCCATGATCTTCCAGAC
TCTTAAACAAACCACATTGTCTTC
CAGTCAGATGTCATACTCACCAAG
AGAGTTTTAGGGACACAGGCAC
GATGACTACTCCAGCACAGACAAC
CTCCTCTTTCACTGGCATC
of the phospholipase A2, group VI (PLA2G6), the pantothenate kinaseG
G
G
C
G
G
G
GTG
TG
TAGG
GAGTG
G
GG
CTTGG
ATG
intronsatrophy in all cases and iron accumulation only in case 6 in
817C. Paisán-Ruiz et al. / Neurobiology of Aging 33 (2012) 814–823the basal ganglia region, typical of NAD, although imaging
was done early on in the disease in cases 3 and 5. Case 4 had
juvenile or atypical NAD with an age of onset in childhood
with dystonia and paroxysmal jerky body movements that
were consistent with myoclonic jerks; an electroencephalo-
gram (EEG) showed right-sided spike and slow wave dis-
charges. Although this patient improved with feeding and
weight gain after a gastrostomy tube was inserted, he con-
tinued to globally progress and died aged 18 years. The case
of death in all cases was aspiration or ventilation-related
pneumonia.
Cases 1 and 2 had a later age of onset, slower disease
progression, and both developed parkinsonian features. Al-
though the overall clinical features of these 2 cases were
different than idiopathic Parkinson’s disease (PD) there is
overlap and both cases are discussed in detail below and
given in Table 2. Case 1 had a diagnosis of “adult-onset
progressive ataxia, spasticity, and parkinsonism”. She had
no relevant past medical or psychiatric history apart from
toe walking. At the age of 18 she had increasing problems
with overt urinary incontinence and constipation. She was
28 years old when presented to a neurologist. Her exami-
nation revealed normal eye movements, mild cerebellar
dysarthria, and ataxia, and mild pyramidal weakness in all
limbs. Brain imaging and central and peripheral electro-
physiology, cerebrospinal fluid (CSF), and muscle biopsy
were all normal. Neuropsychometry suggested mild cogni-
tive decline. These problems progressed, she could no lon-
ger work from age 30 and became wheelchair-bound due to
increasing ataxia and spasticity at the age of 32 years. She
Table 2
Clinical features in the cases with PLA2G6 genetic mutations
Case Age of
onset
Age of
death
First clinical
symptom
Ataxia Dyst
1 18 years 36 years Tripping and prone to
falls
a b
2 22 years 32 years
(alive)
Mood changes and
aggression
c a
3 Infant 8 years Developmental delay Yes b
4 Childhood 18 years Dystonia and
myoclonus
NA d
5 14 months 8 years Developmental delay a b
6 11 months 12 years
(alive)
Psychomotor
retardation
a NA
7 Infantile NA Developmental delay NA NA
As with the PEG, the G-tube is use if patients require long-term tube fee
Key: CT, computerized tomography; EEG, electroencephalogram; G, ; MR
phospholipase A2, Group VI; Yes, symptom present but no severity given
a Severe symptom.
b Symptom not present.
c Mild symptom.
d Moderate symptom.developed psychiatric features with aggression, swallowingdifficulties, and dysarthria and a sensory neuropathy. Par-
kinsonism with rigidity and bradykinesia was first noted at
age 34; this involved the upper limbs and affected the gait
in a symmetrical pattern. Dystonia was absent. Repeat MRI
showed cerebellar atrophy. She further progressed, became
bedbound with severe akinetic rigidity, was mute, and un-
able to communicate. She died of bronchopneumonia at the
age of 36.
Case 2 had a diagnosis of an adult-onset progressive
dystonia-parkinsonism disorder. She was well until the age
of 22 years when she developed psychiatric features with
mood changes, irritability, aggression, and transient visual
hallucinations. She had a rapidly progressive decline in
language abilities and became mute within 9 months. She
also had weight loss and feeding problems. She received
psychiatric treatment including electroconvulsive therapy
and haloperidol, which resulted in extrapyramidal side ef-
fects. These improved rapidly with clozapine as did her
mood. At the age of 24, her extrapyramidal features re-
turned and she developed progressive tremor, bradykinesia,
and micrographia with a shuffling gait and falls. L-dopa
therapy was initially successful but later on in the disease
course she did not respond and developed limb and orofa-
cial dyskinesias a short time after dosing. On examination at
age 28, her higher mental functions were severely impaired
on verbal and nonverbal tests of reasoning. She was hypo-
mimic with reduced visual perceptual and visuospatial
skills. Pursuit eye movements were jerky, and saccades
were slow. She had marked dystonic posturing of all ex-
tremities. Her reflexes were brisk and the plantar responses
Dysphagia Other
Late onset dysphagia requiring
a gastrostomy at age 28
Rigidity and bradykinesia, emotional
and aggressive outbursts, anarthria
c Dystonia, rigidity and bradykinesia,
emotional and aggressive outbursts
a
, gastrostomy Bilateral optic atrophy. MRI 
cerebellar hypoplasia with
hypomyelination
a
, gastrostomy EEG right side slowing and spike
slow wave discharges
d Hearing loss, seizures, cramps, flaccid
tone. CT, EEG normal at 30 months
a
, G-tube inserted for feeding Seizures, hypothermia, bradycardia,
tracheostomy
MRI shows iron deposition
NA NA
netic resonance imaging; NA, information not available; PEG, ; PLA2G6,onia
ding.
I, mag
.were spontaneously extensor. Brain MRI at age 27 years
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rophy. Low signal intensity, indicative of abnormal iron
deposition in the globus pallidus, cerebral peduncles, and
substantia nigra without “eye of the tiger” sign were present
on T2-weighted images. This patient was investigated in
detail for other acquired caused of dystonia and parkinson-
ism; these were normal and included metabolic screening,
muscle, rectal biopsy, and bone marrow biopsies, genetic
testing for SCA1–3, 6, 7, 12, 17, Huntington disease, dysto-
nia 1 gene (DYT1)-related primary dystonia, alpha-sy-
nuclein and dentatorubropallidoluysian atrophy (DRPLA).
After these investigations proved negative a full thickness
right frontal brain biopsy was carried out; these results are
discussed below.
3.1. Mutation analysis
Sequencing of the PLA2G6 gene revealed the presence
f mutations in the examined cases (Tables 2 and 3). Ten
ifferent PLA2G6 mutations were identified and confirmed
y repeat sequencing. Six of them, including frameshift,
issense, splice site, and stop mutations were novel (Table
); conserved in species and not identified in controls. The
novel missense mutations, p.R600Q and p.T572I, were
lso not identified in 548 and 380 control chromosomes,
espectively, and both were conserved across species. Cases
and 6 were homozygous mutations, cases 1, 3, and 5 were
ompound heterozygous. Cases 4 and 7 had single heterozy-
ous mutations. Case 7 was clinically diagnosed with pe-
ipheral nerve pathology. In this case a single heterozygous
utation was identified in the PLA2G6 gene. In cases 4 and
we analyzed the DNA on Human610-Quad-Infinium HD
eadChips to investigate the PLA2G6 gene for deletions.
However, this array platform only contains 14 markers
located in exon 2 and introns 1, 2, 3, 4, 5, 8, and 10 at the
PLA2G6 locus; thus, we could have missed a small
heterozygous deletion affecting only a small part of the
gene. The fact that both mutations are found in heterozy-
Table 3
PLA2G6 gene mutations identified
Case Sex Ethnicity Mutation
F British c.109CT
c.1078 – 3CA
F Greek c.1715CT
M American
Caucasian
c.1061TC
c.1933CT
M American
Caucasian
c.319delC
M American c.610 – 1GT
c.2370delTG
M Hispanic c.1799GA
M Portuguese c.2370TG
ey: AR, autosomal recessive; F, female; M, male; NAD, neuroaxonal dygous states also suggests that if there are deletions at thePLA2G6 locus in these cases, these will not affect the entire
locus. Hence, the PLA2G6 deletions in these cases are
expected to be small and thus not appreciable through the
single nucleotide polymorphism (SNP) genotyping assays.
Case 7 was homozygous for the 14 single nucleotide poly-
morphisms at the PLA2G6 locus, suggesting the presence of
small deletion on 1 allele (likely compound heterozygous
onsense mutation/deletion). Case 4 was homozygous in
everal regions of the gene with a deletion possible of exons
, 5 to 8, or 10 to 17 (Supplementary Material). Because of
he single heterozygous changes identified in cases 4 and 7
nd the lack of absolute proof of a second mutation these 2
ases should be considered only probable PLA2G6 NBIA.
.2. Neuropathology
The neuropathological data are summarized in Table 4.
ross inspection revealed cerebral atrophy in case 5 and
erebellar cortical atrophy was documented in cases 1 and 5.
rusty discoloration of the globus pallidus was found in
ase 4. Severe pallor of the substantia nigra was seen in case
(age at death 36 years). On microscopic investigation the
lobus pallidus contained small clusters of iron-laden mac-
ophages in case 1, while the iron deposition was severe in
ase 4 (Fig. 1A) and widespread in case 5. There were
umerous axonal swellings in case 1, 3, 4, and 5 (Fig. 1B
nd C) in the basal ganglia and brainstem. In case 1 and 5
here the spinal cord was available, there were also numer-
us axonal spheroids in the cord. On hematoxylin and eosin
tained histological sections the axonal swellings appeared
s large spherical structures, up to 100 m in diameter and
were mostly stained with the antineurofilament antibodies.
There was variable depletion of cerebellar cortical neurons
(granular cells more than Purkinje cells) accompanied by
marked astrocytosis in cases 1, 4, and 5 (Fig. 1D), in which
the cerebellum was available for assessment. The substantia
nigra neurons were depleted in case 1. In this case and also
in case 4 Lewy bodies were readily found in the nigra on the
o acid change Type and location Diagnosis
X
e site
Exon 2
Exon 8
Juvenile onset NAD
2I Exon 12
Homozygous
Adult onset NAD
4P
4X
Exon 7
Exon 14
Infantile onset NAD
7FsX4 Exon 3
Heterozygous
Juvenile onset NAD
e site
0X
Exon 5
Exon 17
Infantile onset NAD
0Q Exon 13
Homozygous
Infantile onset NAD
0X Exon 17
Heterozygous
Infantile onset NAD
; PLA2G6, phospholipase A2, group VI.Amin
p.R37
Splic
p.T57
p.L35
p.R65
p.L10
Splic
p.Y79
p.R60
p.Y79hematoxylin and eosin- stained sections. Alpha-synuclein
819C. Paisán-Ruiz et al. / Neurobiology of Aging 33 (2012) 814–823positive Lewy bodies were widespread in cases 1, 4 and 5.
In case 2, where only the biopsy specimen of the frontal
cortex was available, Lewy bodies were frequent. Lewy
bodies were restricted to the medulla in case 3, correspond-
ing to Braak stage 1. In cases 1 and 4 the morphological
appearances and the topographical distribution of the Lewy
body type pathology were comparable to those seen in
severe, end-stage Parkinson’s disease and cases with de-
mentia with Lewy bodies (Halliday et al., 2008; McKeith et
al., 2005). Accordingly, severe Lewy body pathology was
observed in the “dementia with Lewy bodies” consensus
areas, including cerebral cortex, basal forebrain, hippocam-
pal formation, and brainstem nuclei corresponding to “dif-
fuse neocortical Lewy body type pathology” (McKeith et
al., 2005) and Braak stage 6 (Braak et al., 2003) in both case
1 and 4 (Fig. 2A–E). Lewy bodies and Lewy neurites in
nigra and/or cortex were ubiquitin-positive and were con-
firmed to contain alpha-synuclein phosphorylated at Serine
129. In addition, alpha-synuclein accumulation was ob-
served in axonal swellings in all postmortem cases (cases 1,
and 3–5).
There was extensive tau pathology with neurofibrillary
Table 4
Pathological features in the cases with PLA2G6 genetic mutations
Case Amino acid
change
Cortical
atrophy
Cerebellar
atrophy
Ne
sph
1
QSBB
Brain and cord
p.R37X
Splice site
No Yes a
2c
QSBB
Frontal cortical biopsy
p.T572I N/A N/A d
3
NICHD
Brain
p.L354P
p.R654X
N/A N/A e
4
NICHD
Brain
p.L107FsX4 No No a
5g
NICHD
Brain and cord
Splice site
p.Y790X
Yes Yes Ye
6h
NICHD
Sural nerve only
p.R600Q N/A N/A Ye
7h
No tissue
p.Y790X N/A N/A N/A
The sural nerve pathology was from the reporting hospital.
Key: N/A, no information available; No, pathological feature not present;
Brain and Tissue Bank, Baltimore, MD; PLA2G6, phospholipase A2, G
pathological feature present.
a Severity of pathological change severe.
b Severity of pathological change mild.
c Previously reported, formal assessment was performed in the present
d Severity of pathological change absent.
e Severity of pathological change moderate.
f Severity of pathological change very severe.
g Previously reported, no formal assessment in the present study as tiss
h No brain tissue available.tangles, pretangles, and neuropil threads in case 4 corre-sponding to Braak and Braak stage V (Fig. 2F). The AT8-
positive structures were also AT100-positive and Gallyas
silver-positive, which is indicative of tau filaments. Tau-
positive threads and neurofibrillary tangles were restricted
to the transentorhinal cortex in case 1 (Braak and Braak
stage I). There were numerous, tau-positive neuropil threads
in case 2 investigated by a frontal cortical biopsy and
tau-positive glia in hippocampus and entorhinal cortex were
described in case 5 (Galvin et al., 2000).
4. Discussion
We describe the genetic and clinical features of a total of
7 cases with NAD associated with PLA2G6 mutations. An
important addition to the literature provided by this study is
the neuropathological data on cases with varying ages of
onset, including 2 adult onset cases. A wide distribution of
missense, nonsense, and frameshift mutations was identified
in the PLA2G6 gene, which were not identified in controls.
The clinical features in the classical INAD and juvenile
cases were very similar and have been previously well
described. Cases 1 and 2 presented later with ages of onset
al Lewy body pathology Tau pathology
a
Braak stage 6; “diffuse neocortical
Lewy body type pathology”
b
Neurofibrillary tangles and
neuropil threads
a e
Neuropil threads
b Zero
f
Braak stage 6; “diffuse neocortical
Lewy body type pathology”
a
Neurofibrillary tangles and
neuropil threads
Yesg Tau-positive gliag
N/A N/A
N/A N/A
, case from National Institute of Child Health and Human Development,
I; QSBB, case from the Queen Square Brain Bank, London, UK; Yes,
ofaris et al., 2007).
not available (Galvin et al., 2000).uroaxon
eroids
s
s
NICHD
roup V
study (T
ue wasof 18 and 22; they had a slower progression with prominent
r820 C. Paisán-Ruiz et al. / Neurobiology of Aging 33 (2012) 814–823psychiatric symptoms: rigidity, dystonia, and parkinsonian
features. Case 2 responded to L-dopa treatment but was very
sensitive, developing the side effects of worsening dystonia
and dyskinesias. L-dopa was not prescribed in case 1.
Fig. 1. (A) Significant degree of pigment deposition in the globus pallidu
cerebellar cortex in case 1. (C) Large neuroaxonal swellings in the grac
(A and C) Hematoxylin and eosin (H&E); (B and D) phospho-neurofilam
40 m.
Fig. 2. (A and B) Frequent Lewy bodies in substantia nigra neurons in ca
hippocampal subregion (D), and temporal neocortex (E) in case 1. The tau
(A) Hematoxylin and eosin (H&E); (B–E) alpha-synuclein immunohistoc
epresents 80 m.Neuroaxonal dystrophy and alpha-synuclein pathology
with Lewy bodies and Lewy neurites was seen in all cases,
in which the brain was examined postmortem and severe
alpha-synuclein pathology was also confirmed in the case
se 4. (B) Empty baskets highlighting significant Purkinje cell loss in the
eus in case 1, which were often immunoreactive for neurofilament (D).
munohistochemistry (pNF) (RT97 antibody). The bar on (A) represents
evere Lewy pathology is demonstrated in the entorhinal cortex (C), CA2
gy was extensive in case 3 and demonstrated here in the temporal cortex.
y (Syn); (F) tau immunohistochemistry (AT8 antibody). The bar on (A)s in ca
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was also present in 3 postmortem cases (cases 1, 4, and 5)
and the biopsy case (case 2). In cases 1 and 4 the Lewy body
pathology was severe in the neocortex and also in the basal
forebrain, hippocampal formation, and brainstem nuclei
corresponding to Braak stage 6 (Braak et al., 2003) and to
“diffuse neocortical Lewy body type pathology” according
to the consensus criteria established for the diagnosis of
dementia with Lewy bodies (McKeith et al., 2005).
In keeping with previous observations (Gregory et al.,
2008) a striking aspect of our cohort of NBIA type 2 cases
with PLA2G6 mutations and consisting of young individu-
als (age at death ranging between 8 and 36 years), is the
presence of alpha-synuclein pathology, which was severe in
3 cases and in 2 of the postmortem cases it corresponded to
that seen in end stage Parkinson’s disease and dementia
with Lewy bodies (Halliday et al., 2008; McKeith et al.,
2005). The widespread distribution of Lewy bodies in the
brains in our patients may explain the psychiatric features (in
cases 1 and 2) and psychomotor retardation in other cases. The
Lewy bodies in the cases reported here with L-dopa responsive
parkinsonian features and the reported cases with dystonia and
parkinsonism clearly represent a link between cases with
PLA2G6 mutations and Parkinson’s disease. Our observations
are also in line with recent reports of PLA2G6 null mice
showing accumulation of alpha-synuclein in axonal and cyto-
plasmic aggregates (Malik et al., 2008).
In 4 of the cases there was also hyperphosphorylated tau
accumulation in both neuronal processes (threads) and per-
ikarya (pretangles and neurofibrillary tangles) in cases 1 and
4 and in threads in case 2. The tau pathology was subtle and
mostly restricted to the entorhinal cortex in case 1, but was
severe in both mediotemporal structures and frontal and
temporal neocortex in case 4 corresponding to Braak stage
V. In case 2 with disease onset in early adulthood numerous,
tau-positive fine threads were present in the frontal cortical
biopsy specimen. The co-occurence of hyperphosphorylated
tau deposition in these cases is of considerable interest as the
young age of the patients excludes an “age-related, incidental”
phenomenon and amyloid- plaques were not seen in any of
he cases. Codeposition of tau and alpha-synuclein has been
ocumented in both familial PD (Duda et al., 2002) and spo-
adic PD (Ishizawa et al., 2003; Neumann et al., 2009). The
xtent and severity of the tau pathology in some of our cases
nd in a previously reported case with PLA2G6 mutation
Table 5
Sample of atypical cases with adult atypical NAD and parkinsonism show
Case Mutation Age of o
Case 1 (here) p.T572I 18
ase 2 (here) p. R37X/c.1078–3C  A 22
amily 1 p.R741Q 10 and 2
amily 2 p.R747W 18
ranian family p.R632W 21, 22, a
ey: NAD, neuroaxonal dystrophy.Gregory et al., 2008) also raise the possibility of a mechanistic bink not only between PLA2G6 mutations and alpha-synuclein
ccumulation, but also between PLA2G6 mutations and tau
yperphosphorylation and deposition.
The cases reported here all had the neuropathological
eatures of neuroaxonal dystrophy, alpha-synuclein-positive
ewy bodies and Lewy neurites. In all but one case, tau
athology was also present. The clinical features of the
ases reported are different. There is a possible genotype
henotype correlation that may explain the differences be-
ween the classical INAD (childhood) and the late-onset atyp-
cal NAD cases, although the dataset here is small. In the
lassical INAD cases the mutation distribution occurs through-
ut the gene with nonsense and frameshift mutations occurring
ore frequently; these mutations are likely to cause loss of the
LA2G6 functional protein. Atypical cases have a greater
umber of missense and compound heterozygous mutations
oward the 3= prime end of the gene and this is particularly the
ase in the 4 families with adult atypical NAD and parkinson-
sm (Table 5). Families 1, 2, and the Iranian family were
reviously reported (Paisan-Ruiz et al., 2009; Sina et al.,
009). The PLA2G6 mutation position and type may give
ome indication of the possible phenotype, but this is not
omprehensive. Gregory and colleagues recently described
imilar PLA2G6 mutations causing a classical INAD pheno-
ype and a codon 741 mutation (Gregory et al., 2009).
This report further defines the clinical features and neu-
opathology of PLA2G6 related NAD. We particularly
ighlight the role of PLA2G6-related neurodegeneration in
atients with juvenile and adult-onset disease complicated
y dystonia and parkinsonism with normal MRI imaging.
he finding of Lewy body pathology in PLA2G6 bridges a
ink with other neurodegenerative diseases like Parkinson’s
isease and dementia with Lewy bodies and may shed light
n shared pathological pathways.
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